TY - JOUR
AU - Anjorin, AbdulAzeez Adeyemi
AU - Odetokun, Ismail A.
AU - Nyandwi, Jean Baptiste
AU - Elnadi, Hager
AU - Awiagah, Kwame Sherrif
AU - Eyedo, Joseph
AU - Abioye, Ajibola Ibraheem
AU - Gachara, George
AU - Maisara, Aala M O
AU - Razouqi, Youssef
AU - Yusuf Mohamud, Mohamed Farah
AU - Mhgoob, Zuhal E.
AU - Ajayi, Tunde
AU - Ntirenganya, Lazare
AU - Saibu, Morounke
AU - Salako, Babatunde Lawal
AU - Elelu, Nusirat
AU - Wright, Kikelomo Ololade
AU - Fasina, Folorunso O.
AU - Mosbah, Rasha
PY - 2022
DA - April
TI - Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
JO - Vaccines
VL - 10
IS - 4
DO - https://doi.org/10.3390/vaccines10040546
AB - Local, national, and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of safe and effective vaccines is critical in the control of a pandemic. Several adverse events have been reported globally following reception of different vaccines, with limited or no data from Africa. This cross-sectional epidemiological study investigated adverse events following COVID-19 vaccination in Africans from April–June, 2021 using a structured online questionnaire. Out of 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries, including 22 African countries and 13 countries where Africans live in the diaspora, reported adverse events. Over half of the vaccinees were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2, while about one-fourth, 24.8% (n = 240), reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49), while other significant heterogenous events were reported in three categories: very common, common, and uncommon, with the latter including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines.
PB - MDPI
UR - http://researchrepository.napier.ac.uk/Output/3074641
KW - Coronavirus (COVID-19)
ER